April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Prolonged Local Ocular Delivery of an Antibody
Author Affiliations & Notes
  • A. Khalili
    Ocular Repair and Regeneration Biology, UCL Institute of Ophthalmology, London, United Kingdom
    School of Pharmacy, University of London, London, United Kingdom
  • D. Paull
    Ocular Repair and Regeneration Biology, UCL Institute of Ophthalmology, London, United Kingdom
  • J. S. Ellis
    School of Pharmacy, University of London, London, United Kingdom
    NIHR Biomedical Research Center for Ophthalmology, London, United Kingdom
  • S. Dhingra
    Ocular Repair and Regeneration Biology, UCL Institute of Ophthalmology, London, United Kingdom
    NIHR Biomedical Research Center for Ophthalmology, London, United Kingdom
  • P. T. Khaw
    Ocular Repair and Regeneration Biology, UCL Institute of Ophthalmology, London, United Kingdom
    NIHR Biomedical Research Center for Ophthalmology, London, United Kingdom
  • S. Brocchini
    School of Pharmacy, University of London, London, United Kingdom
    NIHR Biomedical Research Center for Ophthalmology, London, United Kingdom
  • Footnotes
    Commercial Relationships  A. Khalili, None; D. Paull, None; J.S. Ellis, None; S. Dhingra, None; P.T. Khaw, Patent, P; S. Brocchini, Patent, P.
  • Footnotes
    Support  School of Pharmacy University of London, NIHR Biomedical Research Center for Ophthalmology, Fight for Sight
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 5992. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Khalili, D. Paull, J. S. Ellis, S. Dhingra, P. T. Khaw, S. Brocchini; Prolonged Local Ocular Delivery of an Antibody. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5992.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the release profile and physicochemical properties of a protein-based ocular delivery device.

Methods: : Bevacizumab (Avastin, Genentech) was fabricated into an implantable solid form. The in vitro release profile of antibody was measured (UV spectrophotometry and surface plasmon resonance) using a flow rig (volume of 200 µl; flow rate of 2 µl/min). The released-antibody was characterized by size exclusion chromatography (SEC), gel electrophoresis, surface plasmon resonance (SPR), dynamic light scattering, and biological assays.

Results: : The active antibody (measured by SPR) was released from our ocular delivery device over a period of approximately 120 hours (within the therapeutic range) and 150 hours for the total antibody (measured by UV spectrophotometry). No shift in the SEC peak of eluted Avastin (76 minutes) was observed. Higher molecular weight species were not observed by SEC or gel electrophoresis, which suggests that there was no significant aggregation. Biological assays also confirmed that activity of Avastin was still preserved after formulation into the ocular delivery device.

Conclusions: : Using Avastin as a model, we are developing a slow release device to allow for the prolonged, local delivery of an antibody.

Keywords: protein structure/function • vascular endothelial growth factor • wound healing 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×